Tags

Type your tag names separated by a space and hit enter

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events.
J Microbiol Immunol Infect. 2019 Feb; 52(1):158-162.JM

Abstract

The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before. This is the first study to evaluate the safety and tolerability of 3HP in this population and revealed a completion rate of 65.4%. The therapy was not associated with hepatotoxicity, but with high rates of adverse events (69.2%).

Authors+Show Affiliations

Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Laboratory Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan; School of Medicine, Graduate Institute of Medicine, Sepsis Research Center, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Biological Science and Technology, College of Biological Science and Technology, National Chiao Tung University, Hsin Chu, Taiwan. Electronic address: infchen@gmail.com.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

29907535

Citation

Lin, Shang-Yi, et al. "Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection in Hemodialysis Patients: High Rates of Adverse Events." Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi, vol. 52, no. 1, 2019, pp. 158-162.
Lin SY, Chiu YW, Lu PL, et al. Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. J Microbiol Immunol Infect. 2019;52(1):158-162.
Lin, S. Y., Chiu, Y. W., Lu, P. L., Hwang, S. J., Chen, T. C., Hsieh, M. H., & Chen, Y. H. (2019). Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. Journal of Microbiology, Immunology, and Infection = Wei Mian Yu Gan Ran Za Zhi, 52(1), 158-162. https://doi.org/10.1016/j.jmii.2018.05.003
Lin SY, et al. Three Months of Rifapentine and Isoniazid for Latent Tuberculosis Infection in Hemodialysis Patients: High Rates of Adverse Events. J Microbiol Immunol Infect. 2019;52(1):158-162. PubMed PMID: 29907535.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events. AU - Lin,Shang-Yi, AU - Chiu,Yi-Wen, AU - Lu,Po-Liang, AU - Hwang,Shang-Jyh, AU - Chen,Tun-Chieh, AU - Hsieh,Min-Han, AU - Chen,Yen-Hsu, Y1 - 2018/06/02/ PY - 2018/02/01/received PY - 2018/04/21/revised PY - 2018/05/07/accepted PY - 2018/6/17/pubmed PY - 2019/9/13/medline PY - 2018/6/17/entrez KW - 3HP KW - Hemodialysis KW - LTBI KW - Latent tuberculosis KW - Rifapentine SP - 158 EP - 162 JF - Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi JO - J Microbiol Immunol Infect VL - 52 IS - 1 N2 - The consequences of once-weekly rifapentine plus isoniazid for 3 months (3HP) against latent tuberculosis infections in hemodialysis patients have not been studied before. This is the first study to evaluate the safety and tolerability of 3HP in this population and revealed a completion rate of 65.4%. The therapy was not associated with hepatotoxicity, but with high rates of adverse events (69.2%). SN - 1995-9133 UR - https://www.unboundmedicine.com/medline/citation/29907535/Three_months_of_rifapentine_and_isoniazid_for_latent_tuberculosis_infection_in_hemodialysis_patients:_High_rates_of_adverse_events_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1684-1182(18)30153-1 DB - PRIME DP - Unbound Medicine ER -